Internal Medicine, Addiction Medicine · West Reading, PA
NPI
1225457641
Since 2014
Specialty
Internal Medicine, Addiction Medicine
Code 207RA0401X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
420 S 5th Ave
West Reading, PA, 19611
Phone (484) 628-5858
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,317
202 services
Medicare patients, 2024
49
Average age 63
Drug cost, 2024
$344K
545 prescriptions
Company payments, 2025
$88.14
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sahithi Gosala was code 99213 (office e&m - established), 74 times for 21 patients. In total Sahithi Gosala billed 202 services in 11 codes, and Medicare paid $9,317.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-01-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 74 | 21 | $59.95 | $4,436 |
| 80305 Drug Tests | Office | 67 | 21 | $12.35 | $827 |
| 99221 Hospital E&M - Initial | Facility | 14 | 12 | $58.52 | $819 |
| 99222 Hospital E&M - Initial | Facility | 14 | 11 | $99.83 | $1,398 |
By year: 2022 $8,375 for 186 services; 2023 $11K for 229 services; 2024 $9,317 for 202 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80305 Drug Tests | 67 | 21 | $12.35 | $827 |
Medicare prescription drug claims, 2024
In 2024, the drug Sahithi Gosala prescribed most often to Medicare patients was Buprenorphine-Naloxone (Buprenorphine Hcl/Naloxone Hcl), with 225 prescriptions and refills. In total Sahithi Gosala wrote 545 Medicare prescriptions that cost $344K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | 225 | 225 | 45 | $36K |
| Sublocade Buprenorphine | 119 | 119 | 22 | $240K |
| Naltrexone Hcl Generic | 47 | 49 | 15 | $1,750 |
| Vivitrol Naltrexone Microspheres | 20 | 20 | Under 11 | $32K |
| Naloxone Hcl Generic | 16 | 16 | 15 | $1,162 |
| Brixadi Buprenorphine | 15 | 15 | Under 11 | $25K |
| Topiramate Generic | 15 | 15 | Under 11 | $35.98 |
| Gabapentin Generic | 13 | 13 | Under 11 | $72.12 |
| Belbuca Buprenorphine Hcl | 13 | 13 | Under 11 | $5,231 |
| Buprenorphine Hcl Generic | 13 | 13 | Under 11 | $324 |
| Disulfiram Generic | 12 | 12 | Under 11 | $499 |
Brand drugs: 172 claims; generic drugs: 373 claims; opioid claims: 14.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sahithi Gosala $88.14 ($88.14 in general payments such as food, travel and fees) from 3 companies. The largest payer was Alkermes, Inc. with $34.88.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.